Albany Molecular Research (NASDAQ:AMRI) was upgraded by investment analysts at McLean Capital Management from a “neutral” rating to a “buy” rating in a note issued to investors on Feb 21st, 2014, Stock Ratings Network reports. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares after opening at $17.01 on last trade day and at the end of the day closed at $18.81. Company price to sales ratio in past twelve months was calculated as 2.45 and price to cash ratio as 15.20. Albany Molecular Research, Inc. (NASDAQ:AMRI) showed a positive weekly performance of 20.42%.
Chimerix Inc (NASDAQ:CMRX) issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. Chimerix Inc (NASDAQ:CMRX) shares advanced 2.80% in last trading session and ended the day on $27.14. CMRX return on equity ratio is recorded as 6.00% and its return on assets is 4.70%. Chimerix Inc (NASDAQ:CMRX) yearly performance is 77.12%.
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company’s plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares moved up 2.15% in last trading session and was closed at $6.19, while trading in range of $5.85 – $6.20. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) year to date (YTD) performance is 111.99%.
LDR Holding Corp (NASDAQ:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced that there have been more than 50,000 implantations of its exclusive VerteBRIDGE(R) plating technology worldwide. Since its introduction in 2007 in France and in 2008 in the United States, VerteBRIDGE technology has grown to a comprehensive platform of products with integrated, zero-profile, in-line plating technology adapted for use in anterior cervical, anterior lumbar, oblique lumbar, and lateral lumbar applications. LDR Holding Corp (NASDAQ:LDRH) weekly performance is 14.03%. On last trading day company shares ended up $38.77. LDR Holding Corp (NASDAQ:LDRH) distance from 50-day simple moving average (SMA50) is 37.68%. Analysts mean target price for the company is $34.60.